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evidence that targeting antigens for proteasomal degradation does not improve the immunogenicity of
DNA vaccines and recombinant VVs. Rather, it is the long-lived antigen that is superior for the efficient
activation of MHC class I-restricted immune responses in vivo. Hence, our results suggest a dominant
role for antigen cross-priming in DNA vaccination and recombinant VV infection.
DOI: https://doi.org/10.1128/JVI.00694-12
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-76864
Originally published at:
Schliehe, Christopher; Bitzer, Annegret; van den Broek, Maries; Groettrup, Marcus (2012). Stable
antigen is most effective for eliciting CD8+ T-cell responses after DNA vaccination and infection with
recombinant vaccinia virus in vivo. Journal of Virology, 86(18):9782-9793.
DOI: https://doi.org/10.1128/JVI.00694-12
  Published Ahead of Print 3 July 2012. 
2012, 86(18):9782. DOI: 10.1128/JVI.00694-12. J. Virol. 
Broek and Marcus Groettrup
Christopher Schliehe, Annegret Bitzer, Maries van den
 
In VivoRecombinant Vaccinia Virus 
Vaccination and Infection with 
 T-Cell Responses after DNA+Eliciting CD8
Stable Antigen Is Most Effective for
http://jvi.asm.org/content/86/18/9782




This article cites 51 articles, 27 of which can be accessed free
CONTENT ALERTS
 more»articles cite this article), 
Receive: RSS Feeds, eTOCs, free email alerts (when new
http://journals.asm.org/site/misc/reprints.xhtmlInformation about commercial reprint orders: 
http://journals.asm.org/site/subscriptions/To subscribe to to another ASM Journal go to: 
 o
n






Stable Antigen Is Most Effective for Eliciting CD8 T-Cell Responses
after DNA Vaccination and Infection with Recombinant Vaccinia
Virus In Vivo
Christopher Schliehe,a Annegret Bitzer,a Maries van den Broek,b and Marcus Groettrupa,c
Division of Immunology, Department of Biology, Constance University, Konstanz, Germanya; Department of Oncology, University Hospital Zürich, Schlieren, Switzerlandb;
and Biotechnology Institute Thurgau at the University of Constance, Kreuzlingen, Switzerlandc
The induction of strong CD8 T-cell responses against infectious diseases and cancer has remained a major challenge. Depend-
ing on the source of antigen and the infectious agent, priming of CD8 T cells requires direct and/or cross-presentation of anti-
genic peptides onmajor histocompatibility complex (MHC) class I molecules by professional antigen-presenting cells (APCs).
However, both pathways show distinct preferences concerning antigen stability. Whereas direct presentation was shown to effi-
ciently present peptides derived from rapidly degraded proteins, cross-presentation is dependent on long-lived antigen species.
In this report, we analyzed the role of antigen stability on DNA vaccination and recombinant vaccinia virus (VV) infection using
altered versions of the same antigen. The long-lived nucleoprotein (NP) of lymphocytic choriomeningitis virus (LCMV) can be
targeted for degradation by N-terminal fusion to ubiquitin or, as we show here, to the ubiquitin-like modifier FAT10. Direct pre-
sentation by cells either transfected with NP-encoding plasmids or infected with recombinant VV in vitrowas enhanced in the
presence of short-lived antigens. In vivo, however, the highest induction of NP-specific CD8 T-cell responses was achieved in
the presence of long-lived NP. Our experiments provide evidence that targeting antigens for proteasomal degradation does not
improve the immunogenicity of DNA vaccines and recombinant VVs. Rather, it is the long-lived antigen that is superior for the
efficient activation of MHC class I-restricted immune responses in vivo. Hence, our results suggest a dominant role for antigen
cross-priming in DNA vaccination and recombinant VV infection.
Vaccination strategies for inducing CD8 T-cell responsesagainst intracellular pathogens and cancer are based on the
major histocompatibility complex class I (MHC-I)-restricted pre-
sentations of antigenic peptides by professional antigen-present-
ing cells (APCs) (37). In these specialized immune cells, two
classes of MHC-I-restricted antigen presentation pathways exist
in parallel that both can be utilized for immunotherapy and vac-
cination. Proteins that are expressed within the APCs are usually
degraded via the ubiquitin/proteasome system (23), and the gen-
erated peptides are translocated into the endoplasmic reticulum
(ER) via the transporter associated with antigen processing (TAP).
Peptides are then loaded onto MHC-I molecules before they enter
the secretory pathway to be presented on the cell surface. This
pathway is referred to as the direct-presentation pathway (5). In
contrast to this, APCs can also acquire exogenous antigens that are
either derived from expression by nonprofessional cells or patho-
gens or are delivered as particulate vaccines. The mechanism fa-
cilitating this way of antigen presentation was discovered by M.
Bevan in 1976 and was later termed cross-presentation (5, 9).
Since both direct and cross-presentation can lead to MHC-I pre-
sentation of antigenic peptides and the priming of naïve cytotoxic
CD8 T cells, they are both interesting targets for vaccinations
aiming at specific CD8 T-cell induction. However, the two path-
ways favor different antigen properties, especially protein stabil-
ity. Generation of peptides for direct presentation was shown to
strongly depend on the formation of defective ribosomal products
(DRiPs) (51). Cotranslational misfolding and rapid proteasomal
targeting leads to an increased generation of peptides, which can
be loaded onto MHC class I molecules. In contrast to this, there
are studies indicating that cross-presentation depends on stable
antigens that are not immediately targeted for proteasomal deg-
radation (7, 16). These biases for differences in antigen stability
have to be taken into account when aiming at the induction of
CD8 T-cell responses by vaccination. However, for many vac-
cines the relative contributions of direct and cross-presentation
have not yet been elucidated. Therefore, it is hard to predict
whether stable or unstable antigens are able to increase the immu-
nogenicity of a particular vaccine.
DNA vaccination is a promising approach to induce MHC
class I-restricted immune responses (27). Despite a relatively low
intrinsic immunogenicity, it has the advantage of combining low-
cost production with easy handling and the independence of a
functional cold chain (12). In recent years, DNA vaccines against
various targets were investigated and published (8). The optimi-
zation of target vectors with improved immunogenicity is cur-
rently a focus of interest. To induce CD8 T-cell responses after
intramuscular (i.m.) injection of DNA constructs, encoded anti-
gens can be directly presented by transfected APCs. If this does not
occur, antigens expressed by muscle and fibroblast cells have to be
cross-presented by professional APCs (47). Depending on the
contribution of both pathways, modification of antigen stability
therefore could provide beneficial immunogenicity for a vaccina-
tion approach using DNA.
Received 19 March 2012 Accepted 24 June 2012
Published ahead of print 3 July 2012
Address correspondence to: Marcus Groettrup marcus.groettrup@uni-
konstanz.de.
Copyright © 2012, American Society for Microbiology. All Rights Reserved.
doi:10.1128/JVI.00694-12
9782 jvi.asm.org Journal of Virology p. 9782–9793 September 2012 Volume 86 Number 18
 o
n






A similar situation is observed for viral vectors that are used for
immunotherapy and vaccination. Genetically modified strains of
vaccinia virus (VV), the effective protective vaccine against small-
pox, were developed as tools to induce immune responses against
recombinant antigens (31). Even though anti-VV responses are
dominated by CD4 T-cell and B-cell responses, the broad spec-
trum of infected cell types offers interesting opportunities to also
induce class I-restricted responses via direct and cross-presenta-
tion. Infection with VV in vivo also targets APCs, which could
allow induction of VV-induced CD8 T-cell responses by direct
presentation. Modification of antigenic stability therefore might
be used to enhance MHC class I-restricted responses.
In this study, we investigated the role of protein stability on
MHC class I presentation after DNA vaccination and infection
with recombinant VV (rVV). As a model antigen, we choose the
long-lived nucleoprotein (NP) of the murine lymphocytic chori-
omeningitis virus (LCMV). LCMV is a frequently used model to
study antiviral immune responses. It belongs to the arenavirus
group and consists of two structural proteins, the NP and the
glycoprotein (GP). Infections with LCMV induce strong NP- and
GP-specific CD8 T-cell responses in mice. The LCMV proteins
were used as model antigens to study direct and cross-presenta-
tion (3, 34). Importantly, for the LCMV NP it was shown that
cross- but not direct presentation is dependent on the long-lived
form of the antigen and is independent of neosynthesis. Addition-
ally, in this system, DRiPs were published to be the major antigen
source for direct presentation (7).
Antigen stability and protein degradation in general are de-
pendent on a complex degradation machinery that maintains
protein homeostasis in the cell. Generally, proteins that are
supposed to be degraded via the proteasome are conjugated to
the 8-kDa protein ubiquitin via a ubiquitin-conjugating en-
zyme cascade (20). This conjugation leads to proteasomal rec-
ognition of the substrate and to its degradation. Besides ubiq-
uitin, there is a family of proteins called ubiquitin-like
modifiers that also can be specifically conjugated to target pro-
teins. However, from all ubiquitin-like modifiers, only the
HLA-F-adjacent transcript 10 (Fat10; 18 kDa) is, like ubiqui-
tin, able to target proteins for proteasomal degradation (21). In
this study, we tried to use ubiquitin-NP as well as Fat10-NP
fusion proteins to shorten the half-life of the LCMV NP model
antigen. This approach allowed us to investigate the role of
antigen stability on immune induction after DNA vaccination
and recombinant VV infection. We show for the first time that
N-terminal fusion of Fat10 to a viral nucleoprotein leads to a
reduction in protein stability, as reported for ubiquitin. Fur-
ther, we provide evidence that protein stability is a critical pa-
rameter that can strongly influence the outcome of a specific
immunization approach. Whereas direct presentation after
transfection or infection with recombinant VV of cell lines in
vitro was increased when introducing short-lived NP-fusion
proteins, this was not observed for DNA vaccination and re-
combinant VV infection in vivo, where stable antigen showed
the highest CD8 T-cell activation. In addition, we found dif-
ferences in the immunogenicity of constructs fused to either
ubiquitin or FAT10, even though their metabolic stability was
similar. Our data indicate that targeting antigens for protea-
somal degradation must not necessarily improve a vaccination
protocol, as has been proposed previously (38).
MATERIALS AND METHODS
Mice, cells, and media. C57BL/6 (H-2b) and BALB/c (H-2d) mice were
originally obtained from Charles River Laboratories and further bred in
the animal facilities of the University of Konstanz. All animals were kept
under specific-pathogen-free conditions in accordance with the rules of
the veterinarian authority of Regierungspräsidium Freiburg and were
used for the experiments at 6 to 12 weeks of age. Primary murine CD8
T-cell lines were cultured in RPMI 1640, 10% fetal calf serum (FCS), 20
U/ml interleukin-2 (IL-2), 50 M -mercaptoethanol, 50 g/ml genta-
micin. The human embryonic kidney cell line HEK293 (19) was main-
tained in Dulbecco’s modified Eagle medium (DMEM), 10% FCS, 100
U/ml penicillin-streptomycin (P-S). The murine fibroblast cell line B8-wt
(H-2d) (22) was cultured in Iscove’s modified Dulbecco’s medium
(IMDM), 10% FCS, 100 U/ml P-S. B8-Db cells are B8 cells stably trans-
fected with H2-Db and were cultured in IMDM, 10% FCS, 100 U/ml P-S,
5g/ml puromycin. MC57 (H-2b) cells are C57BL/6-derived methylcho-
lanthrene-induced fibrosarcoma cells and were cultured in IMDM, 5%
FCS, 100 U/ml P-S (4). Primary murine embryonic fibroblasts were cul-
tured in DMEM, 10% FCS, 100 U/ml P-S. The dendritic cell (DC) line
DC2.4 (H-2b) was kept in RPMI 1640, 10% FCS, 100 U/ml P-S (7). The
human cell line 143B (TK) was maintained in MEM, 10% FCS, 100 U/ml
P-S, 25 g/ml bromodeoxyuridine (BrdU) (ATCC line CRL-8303).
BSC-40 cells are kidney-derived epithelial cells from Cercopithecus ae-
thiops and were cultured in MEM, 10% FCS, 100 U/ml P-S (ATCC line
CRL-2761). Primary peritoneal macrophages were cultured in DMEM,
10% FCS, 100 U/ml P-S. All cell culture media and supplements were
obtained from Gibco, Invitrogen.
GenerationofNPconstructs.TheplasmidspCMV_NPandpCMV_Ub-NP
were kindly provided by L. Whitton (Scripps Research Institute) (38). The
plasmid pCMV_FAT10-NP, encoding an N-terminal Fat10 fusion pro-
tein of the NP, was generated as follows. Mouse Fat10 was amplified by
PCR from pBKCMV_HA-FAT10-GFP (kindly provided by G. Schmidke,
University of Konstanz), generating an N-terminal XhoI and a C-terminal
EcoRI restriction site using the primer pair 5=-TGG TAC CTC GAG ATG
GCT TCT GTC CGC ACC-3= (forward) and 5=-ATA CTA GAA TTC TGC
CAC AGT GCA GTG TGT-3= (reverse), introducing a GG-to-VA muta-
tion at the C-terminal end of the amino acid sequence of Fat10. This
mutation protects Fat10 from being cleaved off the substrate by putative
de-Fat10-ylating enzymes. NP was amplified by PCR from pCMV_NP
using the primer pair 5=-TAT GAT GAA TTC ATG TCC TTG TCT AAG
GAA GT-3= (forward) and 5=-ATC CCC GCG GCC GCT TAG AGT GTC
ACA ACA TT-3= (reverse), introducing an EcoRI and a NotI restriction
site. Both fragments were digested with EcoRI and ligated before Fat10-
VA-NP was amplified by PCR using the primers Fat10_for and the re-
versed primer NP_rev. The amplified Fat10-VA-NP construct was then
introduced into the XhoI/NotI site of pCMV.
Pulse-chase experiment. Analysis of protein stability of different NP
constructs was performed by radioactive pulse-chase experiments, which
were adopted from reference 40. Therefore, the indicated cell types were
either transfected with NP-encoding pCMV constructs using Fugene 6
(Roche) or infected with recombinant VV. Eighteen h after transfection or
3 h after infection, cells were washed two times with phosphate-buffered
saline (PBS) and then incubated in medium lacking methionine (modi-
fied RPMI 1640 medium; R5713; Sigma) for 1 h. After starvation, radio-
actively labeled [35S]methionine was added to the cells in a concentration
of 0.25 mCi/ml for 1 h. [35S]methionine containing radioactive labeling
medium was removed, and cells were washed with PBS and further incu-
bated in medium at 37°C. At the indicated time points, cells were washed
with ice-cold PBS and cell pellets were frozen at 20°C. For lysis, pellets
were resuspended in lysis buffer (50 mM Tris-HCl, pH 8, 150 mM NaCl,
1 mM EDTA, 2% NP-40, protease inhibitors, in H2O) and incubated for
30 min on ice. Afterwards, cell debris was removed by centrifugation and
the radioactivity of the supernatant was quantified using a scintillation
counter (Top Count NXT; Packard). Radioactivity values were used to
adjust supernatants before NP-specific immunoprecipitation (IP). In a
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step of preclearance, protein G beads (Sigma) were added to the cell su-
pernatant for 1 h. Afterwards, beads were removed by centrifugation and
fresh protein G beads were added in the presence of the NP-specific anti-
body KL53 (40). Samples were incubated on a rotator at 4°C. After 18 h,
beads were washed three times with ice-cold NET-TON buffer (650 mM
NaCl, 5 mM EDTA, 50 mM Tris-HCl, pH 8, 0.5% Triton X-100, 1 mg/ml
ovalbumin [Sigma]) and NET-T buffer (150 mM NaCl, 5 mM EDTA, 50
mM Tris-HCl, pH 8), respectively. The beads then were resuspended in
SDS sample buffer, heated for 5 min at 95°C, and loaded onto 10% SDS-
PAGE gels. After electrophoresis, gels were dried and exposed to a radio-
sensitive photo plate. After 24 to 48 h, radioactive bands were visualized
using a phosphorimager (Molecular Imager FX; Bio-Rad).
Generation of specific CD8 T-cell lines. Naive C57BL/6 or BALB/c
mice at 6 to 8 weeks of age were intravenously (i.v.) infected with 200 PFU
LCMV. Starting from 3 weeks after infection, memory mice were used for
the generation of NP396-404- and NP118-126-specific CD8
 T-cell lines.
Spleens from memory mice were homogenized, and isolated splenocytes
were further purified by Ficoll density gradient centrifugation (GE
Healthcare). Splenocytes were further cultured in 6-well plates (1.5 107
cells/well) and directly pulsed with 106 M NP396 or NP118 peptide.
Medium was renewed every second day. On day 5, Ficoll gradient centrif-
ugation was repeated to remove dead cells. Remaining splenocytes were
washed with PBS and further cultured in the presence of IL-2. NP396
(H2-Db)- and NP118 (H2-Ld)-specific CD8 T-cell lines were used be-
tween days 7 and 9 of culture.
Preparation of primary peritoneal macrophages. Peritoneal macro-
phages (pMs) were prepared by intraperitoneal (i.p.) injection of 2 ml
3% thioglycolate solution into either C57BL/6 (H-2b) or BALB/c (H-2d)
mice. After 3 days, peritoneal cells were washed out of the abdominal
cavity using 10 ml of PBS. Cells were cultured for 2 days, and adherent
cells were used for transfection and antigen presentation assays.
In vitro antigen presentation assay. To determine the extent of direct
presentation after transfection of NP-encoding plasmids or infection with
recombinant VV, activation of CD8 T-cell lines was measured in an in
vitro assay. For transfection, cells were electroporated using Amaxa tech-
nology (Lonza). B8-Db cells were harvested and used at a density of 2 
106 cells per 100 l. One g plasmid DNA was used for individual trans-
fections. Electroporation was performed according to the user’s manual
with the MEF2 kit and program A01 of the Amaxa device. One g of
plasmid encoding green fluorescent protein (GFP) was cotransfected as an
internal control to determine transfection efficiency, and cells were cul-
tured in complete medium. After 18 h, cells were harvested and the num-
bers of GFP cells were analyzed by flow cytometry. For analysis of direct
presentation after VV infection, indicated cells were incubated with re-
combinant VV at a multiplicity of infection (MOI) of 10 for 4 h. To
determine antigen presentation of NP-derived epitopes, transfected or
infected cells were titrated in 96-well plates starting with an initial density
of 2  105 cells in 100 l RPMI medium per well. All samples were
prepared in duplicate. NP-specific CD8T cells (2 105) in 100l RPMI
medium containing brefeldin A in a concentration of 20g/ml (2) were
added to each of the wells. After 4 h of incubation at 37°C and 5% CO2,
activation of CD8T cells was determined by intracellular cytokine stain-
ing (ICS) and flow cytometry.
ICS. ICS was performed to detect intracellular accumulation of
gamma interferon (IFN-) as a measure of CD8 T-cell activation. Sam-
ples were centrifuged, and 50l TriColor anti-mouse CD8a (1:200 in PBS;
Invitrogen) was added to each well on ice and incubated for 15 min in the
dark. After samples were washed with ice-cold PBS, 50 l of 3% parafor-
maldehyde (Acros Organics) solution was added for 5 min at room tem-
perature. Afterwards, samples were again washed with PBS. Staining for
IFN- was performed by adding 50-l fluorescein isothiocyanate (FITC)
anti-mouse IFN- (1:1,000; kind gift from M. Basler, University of Con-
stance) in PBS, 1% saponin. The staining was incubated overnight at 4°C.
Before acquisition by flow cytometry (FACScan; BD), samples were
washed, resuspended in PBS, and kept on ice in the dark.
DNA immunization. NP-expressing pCMV plasmids for DNA vacci-
nation were generated in Escherichia coli TOP10 F= and purified using a
plasmid purification kit (Midi plasmid kit; Sigma). Plasmid concentration
was determined by a spectrophotometer (NanoVue; GE Healthcare) and
adjusted to 2 g/l. One hundred g plasmid DNA in 50 l was injected
and electroporated into each of the two hind legs of C57BL/6 mice intra-
muscularly (i.m.) using an in vivo electroporation device (kindly provided
by Ichor Medical Systems, San Diego, CA). DNA immunization was re-
peated two times after 14 and 28 days. On day 7 after the last boost, mice
were sacrificed and splenocytes prepared. The NP396-specific immune
response was quantified by ICS.
Generation of rVV. Recombinant vaccinia virus (rVV) expressing the
LCMV NP was kindly provided by R. Zinkernagel (Zürich University,
Switzerland) (39). rVV expressing ubiquitin-NP (Ub-NP) and Fat10-NP
fusion proteins were generated as follows. NP sequences were introduced
into SalI/NotI restriction sites of the vaccinia transfer plasmid pSC11-S-
B-A-K-N (kindly provided by Bernhard Moss, NIAID NIH), generating
the transfer plasmids pSC11-S-B-A-K-N_Ub-NP and pSC11-S-B-A-K-
N_Fat10-VA-NP. Both constructs were amplified by PCR from pCMV-
Ub-NP/pCMV-Fat10-VA-NP using the primer pair 5=-TAT GAT GTC
GAC ACT CTA GAG GAT CCG GTA C-3= (forward) and 5=-ATC CCC
CCA TGG TTA GAG TGT CAC AAC ATT-3= (reverse), introducing re-
striction sites for 5=SalI and 3=NotI. Generation of rVV was adapted from
reference 44. Briefly, subconfluent 143B (TK) cells were infected with
wild-type VV strain WR at an MOI of 0.1. After 2 h, unbound virus was
removed by addition of fresh medium. After vaccinia virus transfer, plas-
mids were transfected into TK cells using Fugene 6 (Sigma). After 48 h,
medium was removed and cells were embedded in 1% agarose in MEM
containing 10% FCS, 25 g/ml BrdU, 300 g/ml 5-bromo-4-chloro-3-
indolyl--D-galactopyranoside (X-Gal) (Sigma). Plaques that appeared
blue within 6 h were picked and resuspended in 500 l MEM, 2% FCS.
Isolated viral samples were frozen 3 times at 70°C and then used to
reinfect subconfluent TK cells. Purification of plaques was repeated until
in the three following reinfections only blue plaques could be detected.
After the last isolation, rVV were used to infect BCS-40 cells to generate
large amounts of virus. The viral titer of each rVV was determined, and
aliquots were frozen at80°C.
For the generation of enhanced GFP (eGFP) expressing recombinant
vaccinia virus, the insert eGFP (GenBank accession number U55762) was
isolated from pEGFP-N2 (Clontech) by digestion with SmaI and NotI,
followed by blunting. The blunted insert was cloned into the SmaI-di-
gested vector pSC11.3 (32). Recombinant vaccinia virus (rVV) was gen-
erated by homologous recombination over the thymidine kinase gene,
followed by four rounds of plaque purification using blue/white selection
as described previously (30, 32). rVV-eGFP was propagated on BSC40
cells, and its titers were determined.
Virus titer determination. The titer of rVV-infected BSC-40 cell ly-
sates was analyzed after 6 freeze-thaw cycles of cell suspensions. One day
prior to the experiment, BSC-40 cells were plated in 24-well plates to reach
confluence the next day. Lysates of rVV-infected BCS-40 cells were
titrated into 24 wells in 1:10 dilutions, starting with an initial dilution of
1:1,000. In the case of the ex vivo determination of viral titers in ovaries of
infected mice, ovaries were taken on day 4 after infection and physically
disrupted by dounce homogenization in MEM, 10% FCS. Suspensions
were frozen and thawed 6 times. Titrated amounts of lysate were added to
24 wells of BSC-40 cells starting with pure lysate. After infection, BCS-40
cells were cultured in MEM, 10% FCS, 100 U/ml P-S and incubated for 24
to 48 at 37°C, 5% CO2. Afterwards medium was removed and plaques
visualized by addition of 0.5% crystal violet solution for 1 h. Plates then
were washed in a water bath, and plaques were counted to calculate the
number of PFU in the stock lysate.
Determination of viral infection in vivo by flow cytometry.C57BL/6
mice were injected i.p. with 3 106 PFU rVV-eGFP in 200 l PBS. Mice
were euthanized after 15 or 23 h, and spleens were isolated and single-cell
suspensions prepared. Approximately 106 spleen cells were stained with
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anti-I-Ab (MHC-II) PacificBlue and anti-CD11c APC (BioLegend) in 100
l fluorescence-activated cell sorting (FACS) buffer (PBS, 2% FCS, 20
mM EDTA, 0.05% NaN3) for 15 min at 4°C. Cells were washed twice with
2 ml FACS buffer, and the eGFP signal was measured after gating on
CD11cMHC-II dendritic cells. Data were acquired with a CyAn ADP9
flow cytometer (Beckman Coulter) and analyzed with FlowJo software.
To determine the percentage of infected cells 4 h after incubation with all
other recombinant VV, the indicated samples were harvested, washed
with PBS, and fixed using 50l of 3% paraformaldehyde (Acros Organics)
solution for 5 min at room temperature. Afterwards, samples were again
washed with PBS, and staining for intracellular vaccinia virus was per-
formed by adding 50 l FITC anti-vaccinia polyclonal antibody (ab19979;
1:100; Abcam) in PBS, 1% saponin and incubating the samples for 1 h at 4°C.
Before data acquisition by flow cytometry (FACScan; BD Biosciences), sam-
ples were washed, resuspended in PBS, and kept on ice in the dark.
Assessment of immune responses in vaccinia virus-infected mice.
For analysis of immune responses in mice during VV infection, C57BL/6
or BALB/c mice were injected intraperitoneally with 2  106 PFU wild-
type or recombinant VV. Noninjected mice served as controls. On day 8
(direct response) or 21 (memory response) after infection, mice were
sacrificed and splenocytes prepared and restimulated with 106 M either
B8R20-27, NP396-404, or NP118-126 peptide in the presence of 10 g/ml
brefeldin A for 5 h. Afterwards the activation of CD8 T cells was quan-
tified by ICS and flow cytometry.
RESULTS
N-terminal fusionof theLCMVnucleoproteinwithubiquitinor
the ubiquitin-like modifier FAT10 enhances its degradation
rate. Direct and cross-presentation are promoted by distinct
properties of antigens, especially with respect to their degradation
rate. To evaluate the impact of both pathways on vaccination, we
generated three different constructs encoding LCMV NP variants
which are degraded at different rates (Fig. 1A). The LCMV NP
with its two immunodominant epitopes, NP118 (H-2Ld) and
NP396 (H-2Db), was used either without any modification or as a
fusion protein with ubiquitin or FAT10. The C-terminal GG motif
from both ubiquitin and Fat10 was mutated to avoid cleavage by
deconjugating enzymes, before fusion to the N terminus of the
NP. The constructs were cloned into DNA vaccination vectors and
recombinant VV, which were both applied in this study. To show
the altered antigen stability of fusion proteins, we performed ra-
dioactive pulse-chase experiments after transient transfection of
DNA vaccination vectors in HEK293 cells (Fig. 1B) or after infec-
tion with recombinant VV in murine cell lines (Fig. 1C and D).
While no NP-specific immunoprecipitates could be detected in
the nontransfected/infected control, bands of the expected sizes
were found for NP (62 kDa), Ub-NP (70.5 kDa), and Fat10-NP
(80 kDa) constructs in the transfected cells. While in all cases the
NP alone was found to be stable during the 8- to 12-h time period
analyzed, fusion with ubiquitin enhanced the degradation rate of
the NP, leading to almost complete degradation with a half-life of
less than 2 h. Interestingly, fusion to FAT10 also led to a destabi-
lization of the NP, similar to what we have observed for the ubiq-
uitin fusion. The enhanced degradation rates of NP fusion pro-
teins in this experiment validate the NP constructs as adequate for
a comparative study of antigen stability and its effect on antigen
presentation.
Targeting the LCMV NP for rapid degradation increases di-
rect presentation in vitro. We first analyzed the impact of protein
stability on direct presentation after transfection of DNA vaccine
constructs in vitro. To detect possible differences between individ-
ual NP constructs, we first had to ascertain that our transfections
would not lead to saturated antigen presentation with maximal
CD8T-cell activation. Therefore, we titrated the amount of plas-
mid DNA transfected into the antigen-presenting cells (Fig. 2A).
As expected, we observed increasing antigen presentation with the
transfection of increasing amounts of NP-encoding plasmid. Al-
though the best CD8 T-cell activation was observed at concen-
trations of approximately 4g/well of a 6-well plate, we decided to
use 1 g plasmid DNA for all further transfections. This way we
could exclude saturated presentation for individual constructs.
We analyzed the role of antigen stability for direct presentation
in the mouse fibroblast cell line B8Db. DNA constructs were trans-
fected for 18 h, and antigen presentation was analyzed using pri-
mary NP-specific CD8T-cell lines as a read-out system (Fig. 2B).
Interestingly, NP396 as well as NP118 presentation was about 2-
FIG 1 Characterization of protein expression constructs used for the analysis
of antigen presentation after DNA immunization and infection with recom-
binant vaccinia virus (VV). (A) For both DNA and viral constructs, the lym-
phocytic choriomeningitis virus (LCMV) nucleoprotein (NP) was used either
unmodified or cloned in a linear N-terminal fusion with either ubiquitin (Ub-
NP) or FAT10 (FAT10-NP). Arrows indicate the two NP epitopes that were
used in this study to measure antigen presentation, the H2-Ld-restricted
NP118-126 (NP118) and the H2-D
b-restricted NP396-404 (NP396). (B to D)
Pulse-chase experiments to analyze the stability of different NP constructs. (B)
HEK293 cells were transiently transfected; B8Db (C) and DC2.4 (D) cells were
infected with recombinant VV encoding the indicated proteins. All cells were met-
abolically labeled with [35S]methionine. After the indicated time points, cells were
lysed and NP was immunoprecipitated with the anti-NP antibody KL53. Samples
were then separated by SDS-PAGE, dried, and imaged on a radio imager. MG,
proteasome inhibitor MG132. Arrows indicate the size of NP (62 kDa), Ub-NP
(70.5 kDa), and Fat10-NP (80 kDa). Representative results are shown.
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to 3-fold increased after transfection of fusion proteins compared
to the stable wild-type NP, which only led to a basal presentation
of epitopes. Plasmids encoding GFP were cotransfected in all sam-
ples to confirm equal transfection efficiencies by flow cytometry.
Rapid antigen degradation does not enhance immunogenic-
ity of DNA vaccines. In DNA vaccination, constructs encoding
the antigen of interest are usually injected intramuscularly. There-
fore, one can assume that the majority of cells transfected after
DNA injection are muscle cells and cells of the connective tissue.
However, the priming of T-cell responses can only be induced by
professional APCs. Hence, either the number of APCs directly
transfected during DNA vaccination must be large enough to
stimulate immune responses or antigens have to be acquired ex-
ogenously and processed via cross-presentation.
To test whether targeting of antigens for rapid degradation can
be an advantage for the induction of immune responses via DNA
vaccination, we immunized mice with constructs expressing ei-
ther the stable NP or fusion proteins of the NP and ubiquitin or
FAT10 (Fig. 2C). After two booster injections, we analyzed the
immune response in mice by intracellular cytokine staining (Fig.
FIG 2 Evaluation of DNA vaccines after transfection of lymphocytic choriomeningitis virus (LCMV) nucleoprotein (NP)-encoding constructs in vitro and
immunization in vivo. (A) Titration of pCMV NP transfection. Indicated amounts of pCMV NP DNA were transfected into B8Db cells, and presentation of the
epitope NP396 was analyzed by NP396-specific CD8 T cells after 18 h. Antigen presentation was measured by intracellular cytokine staining (ICS). Cotrans-
fection of a GFP-expressing plasmid served as a control. (B) Indicated numbers of B8-Db cells (H-2d/Db) transfected with DNA constructs were analyzed for
NP396- and NP118-specific presentation, which was analyzed after 18 h by coincubation with a constant number of epitope-specific CD8 T cells and ICS. GFP
cotransfection served as a control. The displayed experiment shows representative results for two independent repeats. (C) Experimental setup of in vivo
immunization. Mice were injected and electroporated intramuscularly with 100 g DNA into the limbs on day 0. Homologous boosts were performed on days
14 and 28. On day 34, mice were sacrificed and splenocytes were restimulated with NP396-404 peptide. (D) Representative ICS results for nonimmunized mice
(control) or mice immunized with the indicated DNA constructs. (E) Summary of DNA vaccination results from two independent experiments (n 11). For
better comparison of individual experiments relative CD8 T cells, responses are shown (highest response of each individual experiment was set to 100%) and
were determined using the following equation: relative response (100/percent highest value of IFN- T cells) percent IFN- T cells (sample). Statistical
analysis was performed by unpaired Student’s t test. *, P 0.05.
Schliehe et al.
9786 jvi.asm.org Journal of Virology
 o
n






2D). Interestingly, we found that the percentage of NP396-specific
CD8 T cells was significantly higher in mice immunized with the
construct expressing the stable NP compared to ubiquitin-NP
(Fig. 2E). Responses against the FAT10-NP fusion protein were
also reduced compared to the stable NP, but differences were not
significant. Therefore, our experiments clearly indicate that tar-
geting the LCMV NP for rapid degradation is of no benefit for a
DNA vaccination approach. In contrast, the long-lived protein is
able to induce the strongest immune responses. These findings
have to be taken into account when designing new DNA vaccines.
Enhanced direct presentation of LCMVNP-derived epitopes
after infectionwith recombinantVVsexpressing short-livedNP
fusion proteins in vitro. Recombinant VV was introduced not
only as a potential vaccine against smallpox but also as a tool to
initiate immune responses against various other immune tar-
gets (3). Since optimization of expression constructs is an im-
portant issue for successful vaccination strategies, we were in-
terested in studying the role of antigen stability for the immune
response of a recombinant antigen expressed by VV. Therefore,
we generated recombinant VVs expressing long-lived LCMV
NP or short-lived fusion proteins of the NP with either ubiq-
uitin or Fat10 (Fig. 1).
We wanted to investigate whether differences in antigen stabil-
ity can also influence the direct presentation of antigens after VV
infection. Therefore, we infected various cell types with NP-ex-
pressing recombinant vaccinia virus strains and detected the di-
rect presentation of NP-derived epitopes by NP-specific CD8
T-cell lines and intracellular cytokine staining for IFN- (Fig. 3A).
Interestingly, and similar to our DNA vaccine experiments (Fig.
2B), we found the unstable forms of the NP to be presented with
significantly higher efficiency than epitopes derived from the
long-lived NP. This observation was true for both epitopes ana-
lyzed, the NP396 and the NP118, and it was valid both 4 (Fig. 3A)
and 2 h (Fig. 3B) after infection, indicating that this was not a
kinetic effect. Additionally, a direct comparison of the two NP
fusion proteins Ub-NP and Fat10-NP reveals that Fat10-NP seems
to present with the highest efficiency of all cell types and epitopes
analyzed. Antigen presentation and activation of CD8T cells was
not saturated, since differences were observed for all titrated tar-
get-to-effector (T/E) ratios.
Small differences in infection rates might lead to changes in
antigen presentation. To analyze the impact of such differences,
we mixed different types of peptide-pulsed and nonpulsed cells at
the indicated ratios and measured the activation of CD8 T-cell
lines (Fig. 3C). While there were strong differences in antigen
presentation with increasing amounts of peptide-loaded cells in
the low range, activation was almost saturated with around 50%
peptide-loaded cells, and no major differences between cell types
were recorded. Moreover, a titration of NP118 and NP396 pep-
tides revealed that the NP118- and NP396-specific T-cell lines
were of the expected sensitivity, with a detection threshold of 109
M for NP118 and 1010 M for NP396 (Fig. 3D). As an additional
control to show equal infection rates of recombinant VV for all
cell types used, we performed intracellular vaccinia virus stainings
and analysis of infected cells by flow cytometry. As indicated in the
bar graph (Fig. 3E, bottom), the infection rates for NP, Ub-NP,
and Fat10-NP were similar in all cell types tested. From these
controls, we conclude that differences in antigen presentation
seen for recombinant VV-infected cells were due to intrinsic prop-
erties of the antigens encoded.
Stable antigen shows the strongest CD8T-cell responses in
mice after infection with recombinant vaccinia virus in vivo.
After analyzing direct presentation in vitro, we were interested in
studying the role of antigen stability after VV infection in vivo. In
an initial experiment, we compared the viral titers of wild-type
vaccinia virus and the different recombinant VV on day 4 after
infection to ensure that possible differences in immune induction
were not due to alterations between individual virus clones (Fig.
4A). While no virus could be detected in ovaries of uninfected
mice, comparable titers of virus were found in mice infected with
wild-type and recombinant VVs. No significant difference could
be calculated between individual virus strains. CD8 T-cell re-
sponses against vaccinia virus in C57BL/6 mice are dominated by
the B8R protein-derived epitope B8R20-27. As an additional con-
trol, we compared the B8R-specific immune responses in mice
immunized with either wild-type VV or different rVV strains (Fig.
4B). Since the only difference between individual viruses is the
introduction of NP and NP derivatives, the B8R-specific response
should be similar in mice infected with all viruses. In fact, there
was no significant difference in the B8R-specific immune response
on day 7 after infection with wild-type VV and the recombinant
VV clones NP and Ub-NP and only slightly higher numbers of
B8R-specifc CD8 T cells in mice immunized with the rVV ex-
pressing Fat10-NP. When we analyzed the activation of NP-spe-
cific CD8 T cells, we observed the highest induction in mice
injected with the recombinant VV expressing the long-lived form
of the NP (Fig. 4C and D). In contrast to this, there was hardly any
response detectable in mice immunized with the virus expressing
the short-lived Ub-NP. A similar result was obtained when ana-
lyzing memory mice 3 weeks after VV infection (Fig. 4E and F).
Since there was no difference in viral propagation and induction
of B8R-specific immune responses between mice infected with
rVV-NP, rVV-Ub-NP, and wild-type VV (Fig. 4B), we con-
clude from these experiments that the stable antigen is superior
in inducing CD8 T-cell responses after vaccinia virus infec-
tion in this system. However, an intermediate phenotype was
observed in the CTL responses after infection with recombi-
nant VV expressing Fat10-NP (Fig. 4C and G). CD8 T-cell
responses were significantly stronger than those of rVV Ub-
NP, but they failed to reach the level of NP396-specific re-
sponses elicited by rVV NP, whereas the memory responses to
NP118 in BALB/c mice elicited by infection with rVV NP and
rVV FAT10-NP were equally strong (Fig. 4F).
Finally, we investigated whether the striking difference be-
tween short-lived and long-lived variants of NP with respect to
NP118 and NP396 antigen presentation in vitro compared to
CD8 T-cell priming in vivo was due to the inability of the used
rVV strain to infect DC in mice. C57BL/6 mice were infected with
rVV expressing GFP (rVV-GFP), which resulted in GFP expres-
sion in MHC-IICD11c cells and MHC-IICD11cDCs in the
spleen 15 and 23 h after infection, strongly suggesting that rVV-
GFP had infected DCs in vivo (Fig. 5). Therefore, we conclude that
the inferior induction of NP-specific CTL responses by rapidly
degraded variants of NP compared to stable NP in vivo cannot be
attributed to the inability of the used rVV strain to directly infect
CD11c dendritic cells.
DISCUSSION
The development of novel vaccines against infectious diseases and
cancer is still a challenging field of biomedical research. Immuno-
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genicity, biological safety, and cost efficiency are key words often
discussed in connection with the requirements of novel vaccines.
However, biological safety and high immunogenicity are espe-
cially important parameters, and they are often mutually exclu-
sive. In this report, we studied the molecular requirements of an-
tigen stability for two kinds of vaccines that are promising
candidates for future immunotherapy and vaccination.
DNA vaccines combine many advantages as tools in clinical
FIG 3 Direct presentation of NP epitopes in vitro after infection of the indicated cell lines with recombinant vaccinia viruses (VV) encoding either the long-lived
lymphocytic choriomeningitis virus nucleoprotein (NP), short-lived fusion proteins of the NP with either ubiquitin (Ub-NP) or FAT10 (FAT10-NP), or
wild-type vaccinia virus as a control. Four h (A) or 2 h (B) after infection, cells were washed with PBS and the indicated dilutions were incubated with 2 105
CD8 T cells specific for the NP epitopes NP396 (H2-Db) and NP118 (H2-Ld). Activation of CD8 T cells was analyzed by intracellular cytokine staining (ICS)
for gamma interferon (IFN). Results are representative of two independent experiments. (C) Analysis of transfection/infection efficiency on CD8 T-cell
activation. Indicated cells were either left untreated or pulsed with NP peptides for 1 h at 37°C. Pulsed and nonpulsed cells were mixed in titrated ratios to a final
concentration of 2 105 cells/well. CD8T cells were added in the same concentration, and their activation was analyzed by ICS. (D) Titration of peptide antigen
sensitivity of CTL lines as used in panels A to C. Restimulated T cells lines with the indicated specificity for NP118 and NP396 were treated with the indicated
concentrations of peptide for 3 h in the presence of brefeldin A and subsequently subjected to intracellular IFN- staining and flow-cytometric analysis. The
experiment has been repeated twice with a similar outcome. (E) Intracellular staining for vaccinia virus. Indicated cells were infected with the indicated
recombinant VV for 4 h. Afterwards cells were fixed and intracellularly stained with FITC-conjugated anti-vaccinia antibody. A representative flow cytometric
analysis and a graph bar of two experiments performed with mean values and SEM are shown.
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immunology (8). Current approaches that intend to enhance
DNA-mediated immune responses include various delivery sys-
tems (e.g., electroporation and gene gun), coadministration of
cytokines, or other proinflammatory molecules (26). Although
CD4 T-cell responses can be induced by DNA vaccination, the
majority of studies concentrate on the initiation of CD8 T-cell
responses, since these cells are important for clearing infected or
malignant cells. There is an ongoing debate on the molecular
mechanisms involved in the initial priming of CD8 T cells after
DNA vaccination. Of special interest are the cell types involved in
antigen priming and whether direct or cross-presentation ac-
counts for antigen-specific responses. Initial studies in the 1990s
have clearly identified DCs as the major APC type in charge of
priming CD8 T cells after DNA vaccination (24). Because the
vast majority of antigen after intramuscular injection of DNA is
produced by myocytes (15), it was questioned whether direct pre-
sentation by the relatively low number of transfected APCs could
account for the overall CD8 T-cell priming, as documented in
some reports (1, 35). For cross-presentation, antigens expressed
by myocytes and other tissue-specific cells would have to be trans-
ferred to APCs that can internalize exogenous antigens and pres-
ent peptides in the context of MHC class I. Indeed, such a transfer
of antigens from myocytes to APCs was formally shown and asso-
ciated with antigen cross-presentation (17). The understanding of
the antigen presentation pathway after DNA immunization is im-
portant to further enhance its immunogenicity.
In this study, we investigated the role of antigen stability on the
efficiency of DNA vaccination. By N-terminal fusion of the LCMV
NP to either ubiquitin or Fat10, we were able to convert the long-
lived nature of the NP into rapidly degraded derivatives that re-
FIG 4 Analysis of CD8 T-cell responses in mice immunized with different recombinant vaccinia viruses (VV). (A) Comparison of viral titers in ovaries of C57BL/6
mice on day 4 after infection to wild-type vaccinia virus, recombinant VV expressing either the long-lived lymphocytic choriomeningitis virus (LCMV) nucleoprotein
(NP), the short-lived fusion proteins with ubiquitin (Ub-NP) or FAT10 (FAT10-NP), or with PBS as a control (no). Results are indicated in PFU per one pair of ovaries.
(B to F) Spleens of infected and control mice (no) were removed on day 8 after infection, and splenocytes were restimulated in vitrowith the VV epitope B8R (B) or the
LCMV epitope NP396 (C) or NP118 (D). (E and F) Mice were infected as described above, and splenocytes were restimulated 3 weeks after infection (memory response)
with LCMV epitope NP396 (E) or NP118 (F). After 5 h, CD8T-cell activation was analyzed by intracellular cytokine staining (ICS) for gamma interferon, and samples
were analyzed by flow cytometry. (G) Representative ICS stainings for an experiment as described in panel C. Dot plots shown in panels C to F show the percentages of
IFN--positive cells of all CD8 lymphocytes; each dot represents the results from one mouse analyzed. Combined results from three independent experiments are
shown. For better comparison of individual experiments, relative CD8T-cell responses are shown (% rel. CD8T-cell resp.). The highest response of each individual
experiment was set to 100%. Relative response (100/percent IFN-T cells [highest value]) percent IFN-T cells (sample). Statistical analysis was performed by
using an unpaired Student’s t test with Welch’s correction if variances were significantly different: *, P 0.05; **, P 0.01; ***, P 0.001.
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semble the viral protein in all parameters (e.g., epitopes and ex-
pression profile) except its half-life (Fig. 1). Rapidly degraded
proteins and DRiPs were found to be the major sources of the
direct MHC class I antigen presentation pathway (5, 51). In accor-
dance with these findings, one would assume that proteasomal
targeting of an antigen can lead to enhanced direct presentation.
By transfecting mouse fibroblasts, we could show that ubiqui-
tin-NP and Fat10-NP fusion proteins are more efficiently pre-
sented in vitro than the construct expressing the long-lived wild-
type NP (Fig. 2). This experiment argues against a DRiP-only
hypothesis in direct MHC class I presentation, because additional
degradation of normally stable proteins seems to enhance the pep-
tide load.
The dependence of direct presentation on rapid protein deg-
radation, in combination with the finding that cross-presentation
of the LCMV NP entirely depends on the stable antigen (7, 16),
allows an interpretation of our findings concerning the general
mechanism of antigen presentation in DNA vaccination in vivo. If
direct presentation by APCs would be the major mechanism, pro-
teasomal targeting of the antigen should enhance CD8 T-cell
activation, as seen in vitro. Vice versa, the long-lived wild-type
protein should give the best results if a response is based on cross-
presentation. Interestingly, we found the strongest immune acti-
vation in mice that were immunized with the long-lived wild-type
NP. The responses after injection of ubiquitin-NP were signifi-
cantly reduced. This finding contradicts an earlier study with the
opposite results using the same NP constructs (38). However, in
that study the authors could only indirectly show the NP-specific
immune responses by analysis of viral clearance after an LCMV
infection that was performed weeks after immunization. This
rather indirect method was required because the low intrinsic im-
munogenicity of DNA constructs did not allow direct ex vivo anal-
yses. We circumvented this difficulty by using a novel electropo-
ration device as a tool to enhance immunogenicity, as also
demonstrated by other recent studies (8). Thus, we were able to
analyze CD8 T-cell responses directly ex vivo, which makes our
results more reliable and allows a different interpretation of the
data: cross-presentation of DNA-encoded antigens has to make a
major contribution to the overall immune response to DNA vac-
cines. Otherwise, we could not explain why short-lived NP fusion
proteins show enhanced antigen presentation in vitro but reduced
responses in vivo. Our data are in accordance with a similar study
showing the requirement of the stable NP of influenza A virus in
DNA tattoo vaccination in order to induce effective immune re-
sponses (11). Other lines of evidence indicate cross-presentation
of DNA-encoded antigens after DNA immunization. In a cellular
transfer model, it was shown that donor-restricted immune re-
sponses were still initiated in mice if APCs were injected as long as
21 days after DNA immunization (14). It is therefore likely that
antigens expressed by other cell types were acquired and immune
responses induced via cross-presentation. Strong evidence for a
role of cross-presentation also comes from two studies showing
efficient CD8 T-cell priming in mice that were immunized with
DNA constructs expressing the antigen under a tissue-specific
promoter not active in APCs (13, 29). Assuming tight promoter
regulation, these studies show that DNA-mediated immune re-
sponses can be entirely independent of direct presentation. Since
our experiments did not show total inhibition of immune re-
sponses after targeting of the LCMV NP for rapid degradation, we
conclude from our experiments that cross-presentation as well as
FIG 5 Infection of dendritic cells with rVV-GFP in vivo. C57BL/6 mice were injected i.p. with 3 106 PFU rVV-eGFP. At 15 or 23 h after infection, mice were
euthanized and splenocytes were stained with anti-I-Ab (MHC-II) and anti-CD11c antibodies. MHC-II CD11c and MHC-II CD11c cells were gated as
indicated, and eGFP fluorescence was assessed by flow cytometry. The experiment has been reproduced twice with similar outcomes.
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direct presentation contribute to the overall priming of CD8 T
cells after DNA immunization. This idea fits well with recent stud-
ies showing a redundant function of direct and cross-presentation
in similar approaches (36, 48). Depending on the nature and dose
of antigen, both pathways seem to be possible (25).
Compared to DNA vaccines, recombinant VV vaccines have
the advantage of showing significantly higher transfection/infec-
tion efficiency that leads to the expression and presentation of
recombinant antigens. Similar to the situation described above,
the extent to which direct and/or cross-priming contributes to the
initial CD8T-cell activation after infection with VV has not been
elucidated definitively. We generated recombinant VV strains that
either express the long-lived wild-type form of the LCMV NP or
short-lived fusion proteins of NP with ubiquitin or Fat10. Similar
to our DNA data, we found enhanced direct presentation in vitro
if cells were infected with recombinant VV strains expressing the
short-lived fusion proteins (Fig. 3). Due to efficient infection of
VV, we could analyze various murine cell types that all showed
similar results. Interestingly, cells infected with recombinant VV
expressing Fat10-NP resulted in the highest level of CD8 T-cell
activation in a number of cell lines. This is in line with the rapid
degradation kinetic of Fat10-NP (Fig. 1). The fact that destabili-
zation of antigens can lead to increased antigen presentation in
vitro was already shown in an earlier publication by reducing the
half-life of an influenza virus NP via the N-end rule (46).
Interestingly, our studies indicated different antigen prefer-
ences for CD8T-cell priming in vivo. The recombinant VV strain
expressing the long-lived wild-type form of the NP was found to
be most potent in inducing CD8 T cells in primary as well as
memory responses (Fig. 4). In contrast to this, the short-lived
ubiquitin-NP induced only weak responses. These findings are
especially striking because there was no difference in viral replica-
tion in vivo and in responses to the VV epitope B8R. Moreover, we
could not exclude that the vaccinia virus strain used in this study
infected dendritic cells, as infection of mice with rVV-GFP led to
prominent GFP expression, especially of MHC-II CD11c DCs
but also of MHC-II CD11c cells (Fig. 5). This result strongly
suggests that DCs were directly infected with rVV-GFP, because
an endocytic uptake of GFP cells would lead to rapid degradation
of GFP in endolysosomes of DC and quenching of the acid-sensi-
tive fluorescence of GFP. It appears that a direct infection of DC
with VV and synthesis of rVV-encoded proteins in them never-
theless does not lead to a superior priming of NP118- and NP396-
specific T cells in vivo by rapidly degraded Ub-NP or FAT10-NP. It
is possible that rVV-infected DC contribute little to T-cell prim-
ing, because VV lyses cells shortly after infection, which may hin-
der T-cell priming, which is known to rely on a long-lasting DC–
T-cell interaction in vivo. Alternatively, VV replication may limit
the priming potential of DC by downregulating factors needed for
T-cell stimulation, like cytokines or costimulatory receptors.
In line with our data on DNA vaccination, our results clearly
favor a dominant, if not exclusive, role of cross-presentation for
MHC class-restricted immune responses after VV infection. In-
terestingly, a very similar study with equal results was performed
using a recombinant VV expressing either the long-lived tyrosi-
nase or a short-lived ubiquitin fusion (18). Also in this study, the
wild-type protein was much more potent in inducing immune
responses than its short-lived derivative. In a different report, co-
expression of inhibitory proteins of cytomegalovirus that block
direct presentation reduced responses to a recombinant antigen
(6). Therefore, the authors argued that cross-presentation of viral
antigens is a mechanism to overcome viral evasion strategies in
case direct presentation is inhibited. Rapid degradation of antigen
was also shown to inhibit CD8 T-cell responses against other
viruses, like vesicular stomatitis virus, Sendai virus (28), and oth-
ers (43).
There are very few studies that are in favor of direct presen-
tation as the dominant mechanism in VV infection. Surpris-
ingly, proteasomal targeting of HIV antigens was shown to
increase CD8 T-cell induction (45), which is in contrast to the
previously mentioned studies and our results. Other reports
showed an importance of direct presentation (6, 42). A study
using the HIV protein Gag showed increased presentation of
unstable antigen in vitro, but differences between long- and
short-lived antigens in vivo have not been detected (49). The
reason for differences between our and the aforementioned
studies are unclear but might be due to HIV-specific antigen
properties. Overall, we conclude that antigen cross-presenta-
tion is an important mechanism to induce CD8 T-cell re-
sponses after VV infection, an idea that is in line with studies on
other cytopathic viruses (41). There are ideas to increase im-
munogenicity of recombinant vaccines by expression of mini-
genes (2, 50). However, we cannot support this idea with our
data. Additionally, recombinant VVs expressing minigenes of
CD8 T-cell epitopes were shown to fail in inducing immune
responses via cross-presentation in vivo, while direct presenta-
tion in vitro was efficient (33). The few exceptions that appear
in the literature most probably are due to special properties of
the antigen used and should not be overestimated compared to
the increasing number of reports in favor of cross-presenta-
tion.
Finally, it has to be discussed to what extent Fat10 fusion to
the LCMV NP alters its potential in antigen presentation and
CD8 T-cell priming. In our in vitro transfection experiments,
we detected better direct presentation for the Fat10-NP con-
struct than the fusion protein ubiquitin-NP. Considering this
fact and the rapid degradation rate of Fat10-NP, one could
assume a loss of immunogenicity in DNA vaccination and re-
combinant VV infection that is similar to what we observed for
ubiquitin-NP. However, in all of our in vivo experiments, the
Fat10-NP constructs showed an intermediate phenotype. In
both systems, the NP-specific responses of Fat10-NP were
stronger than those of the virus expressing ubiquitin-NP.
Memory responses in BALB/c mice showed the highest level of
T-cell activation for the Fat10-NP-expressing VV. This obser-
vation cannot be explained yet. However, although viral repli-
cation was similar for the Fat10-NP-expressing strain, we ob-
served significantly higher responses to the vaccinia epitope
B8R. Therefore, the enhanced presentation could be due to
effects not related to the Fat10 construct but to uncharacterized
differences in the viral strains.
Apart from this difference, one could speculate that Fat10-
mediated degradation leads to a different pathway from those
occurring after modification with ubiquitin. It was shown in
numerous publications that not only stable proteins but also
stabilized peptides in association with cellular factors like heat
shock proteins (HSPs) can be an efficient source of antigen for
cross-presentation (10). Here, we speculate that intermediates
of Fat10-NP but not ubiquitin-NP are stabilized to represent
an antigen source for cross-presentation. This way, the IFN--
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inducible Fat10 would allow the stabilization of antigens dur-
ing inflammation that would normally be prone to ubiquitiny-
lation and degraded into small peptides that have no access to
the cross-presentation pathway. However, we have no evidence
for such a pathway, the discovery of which could provide novel
insights into the biology of Fat10 to further distinguish its
function from that of ubiquitin.
The results presented in this report provide strong evidence
that stable antigens should be preferentially used to achieve
robust immune responses after DNA vaccination and infection
with recombinant VV. Our results are in accordance with other
studies showing the importance of cross-presentation in these
systems and should be taken into account for the development
of novel vaccination strategies that aim to improve immuno-
genicity.
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